로딩 중...
52주 최고가 대비 72.5% 위치
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
SEC 13F 공시 기준 · 2026-Q1
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2021년 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $26.64B | $23.89B | $23.88B | $24.57B |
| 영업이익 | - | $7.54B | $5.20B | $4.86B | $4.69B |
| 당기순이익 | - | $7.21B | $4.76B | $3.90B | $3.61B |
| 잉여현금흐름 (FCF) | - | $7.40B | $5.78B | $5.30B | $5.26B |
| 수익성 비율 | |||||
| 영업이익률 | - | 28.3% | 21.8% | 20.4% | 19.1% |
| 순이익률 | - | 27.1% | 19.9% | 16.3% | 14.7% |
| ROE (자기자본이익률) | - | 14.4% | 8.9% | 7.9% | 6.9% |
| ROA (자산이익률) | - | 8.5% | 5.6% | 5.0% | 4.3% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | -10.3% | -0.1% | 2.9% |
| EPS 성장률 (YoY) | - | - | -34.0% | -17.1% | -4.5% |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | 23.8x | 37.1x | 41.8x | 43.3x |
| PBR (주가순자산배수) | - | 3.3x | 3.1x | 3.2x | 2.9x |
| PSR (주가매출배수) | - | 6.1x | 7.0x | 6.5x | 6.3x |
| FCF Yield | - | 4.5% | 3.4% | 3.4% | 3.4% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | 0.41 | 0.37 | 0.35 | 0.37 |
| 유동비율 | - | 1.89 | 1.68 | 1.40 | 1.87 |
MOLINA HEALTHCARE INC
$179.86
$9.4B